August 21, 2017 6:54 AM ET

Pharmaceuticals

Company Overview of Zavante Therapeutics, Inc.

Company Overview

Zavante Therapeutics, Inc. manufactures pharmaceutical products such as antibacterial agents to treat serious infections. The company was incorporated in 2013 and is based in San Diego, California. As of May 5, 2015, Zavante Therapeutics, Inc. operates as a subsidiary of SG Pharmaceuticals, Inc.

3888 Quarter Mile Drive

San Diego, CA 92130

United States

Founded in 2013

Phone:

858-705-2365

Key Executives for Zavante Therapeutics, Inc.

Founder, Chief Executive Officer and President
Age: 62
Founder and Chairman
Age: 69
Compensation as of Fiscal Year 2017.

Zavante Therapeutics, Inc. Key Developments

Zavante Therapeutics, Inc. Presents at BIO International Conference 2017, Jun-20-2017 01:45 PM

Zavante Therapeutics, Inc. Presents at BIO International Conference 2017, Jun-20-2017 01:45 PM. Venue: San Diego Convention Center, San Diego, CA 2865, United States. Speakers: Evelyn Ellis-Grosse, co-founder and chief scientific officer.

Zavante Therapeutics Reports Completion Of Patient Treatment In The ZEUS Study Of ZTI-01

Zavante Therapeutics, Inc. announced the completion of patient recruitment and treatment in the ZEUS multinational pivotal clinical trial of  TI-01 (fosfomycin for injection).  ZTI-01 is an investigational antibiotic intended for the treatment of hospitalized patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). ZTI-01, the Company's lead product candidate, is a first-in-class, broad spectrum intravenous antibiotic under development in the U.S. to treat serious infections, including those caused by MDR Gram-negative pathogens. ZTI-01 is a first-in-class injectable antibiotic with a mechanism of action that differs from all other antibiotics. ZTI-01 has demonstrated a broad spectrum of bactericidal activity in vitro against both Gram-negative and Gram-positive bacteria, including activity against most contemporary MDR strains. FDA granted Fast Track designation and Qualified Infectious Disease Product (QIDP) designation for the investigation of ZTI-01 for the following indications: cUTI, Hospital-Acquired Bacterial Pneumonia (HABP), Ventilator-Associated Bacterial Pneumonia (VABP), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Complicated Intra-Abdominal Infections (cIAI).

Zavante Therapeutics, Inc. Appoints Stephen L. Newman to its Board of Directors

Zavante Therapeutics, Inc. announced the appointment of Stephen L. Newman, M.D., to its board of directors. Dr. Newman currently serves as Chairman of the Board of CentraForce, LLC. He also serves as Chairman of the JDRF Research Committee and recently completed a term as Vice Chairman of the International Board of Directors of JDRF.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Zavante Therapeutics, Inc., please visit www.zavante.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.